Scienture Holdings, Inc. SCNX
NASDAQ · United States · Commercial Services
$0.1771-0.08 (-31.83%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has determined to effect a reverse stock split of its outstanding shares of common stock at a rati
Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in annual sales across 9.8 million units COMMACK, NY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.